NovoCure Ltd
NVCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.84B
Close$
$-8.49
148.1% downside
Current Fair Value
148.1% downsideOvervalued by 148.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.84 Billion |
|---|---|
| Enterprise Value | $1.98 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 0.94 |
| Outstanding Shares | 114,149,838 |
Return
| Return on Equity | -44.92% |
|---|---|
| Return on Assets | -18.86% |
| Return on Invested Capital | -27.17% |
Valuation & Multiples
| P/E Ratio | -10.41 |
|---|---|
| PEG | 17.06 |
| Price to Sales | 2.94 |
| Price to Book Ratio | 8.83 |
| Enterprise Value to Revenue | 2.83 |
| Enterprise Value to EBIT | -12.79 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.71 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$172.44 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$180.99 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 74.42% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.34%▼ 88.37% |
|---|---|
| Total Invested | $5.96M▼ 99.45% |
| Investors Holding | 19▼ 212.00% |
ESG Score
No data
About NovoCure Ltd
CEO: Asaf Danziger